U.S. Drug-Maker Delegation Lobbies India Against Compulsory Licenses
This article was originally published in PharmAsia News
Merck, Mylan and Pfizer were U.S. drug-company officials who met recently with India's Department of Industrial Policy & Promotion in a lobbying effort to block compulsory licenses of their products, according to a source.
You may also be interested in...
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.